GLP-1s & Weight Loss
Route(s)
Subcutaneous
Typical dose
0.25mg
Dosing window
Anytime
Receptor / target
Amylin
Properties
Incretin
Pre-mixed
No
Cagrilintide
← Back to Library
Human trial protocol FDA safety flag Protocol not independently verified Satiety Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Cagrilintide is reviewed here for weight loss, blood sugar, and appetite regulation.
Research Summary
Evidence Strength
Moderate
Primary Evidence
Human studies, published literature, supporting research
Research Focus
Weight loss, Blood sugar, Appetite regulation
Mechanism
Target context: Amylin
Long-Term Data
Human data exists, but longer-term context is still developing.
Current Consensus
Human research exists, but confidence depends on product, dose, and population.
Route(s)
Subcutaneous
Typical dose
0.25mg
Dosing window
Anytime
Receptor / target
Amylin
Properties
Incretin
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.25mg once weekly | Initiation phase. |
| Weeks 5-8 | 0.5mg once weekly | Standard dose. |
| Weeks 9-12 | 1.0mg once weekly | Advanced escalation. |
| Weeks 13+ | 2.4mg once weekly | Maximum dose. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative: Micro-Stacking
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 0.125mg to 0.25mg once weekly | When stacked with Tirzepatide or Semaglutide, kept very low to avoid extreme gastric paralysis. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (Amylin); route Subcutaneous; timing Anytime. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | Investigational compound or combination. Human trial evidence may exist, but there is no FDA-approved label for routine use. |
|---|---|
| Where studied | Studied mainly in obesity, type 2 diabetes, appetite regulation, cardiometabolic risk, and metabolic liver-disease settings depending on the molecule. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Amylin. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | Human-trial anchor: Phase 2 dose-finding trial: once-weekly SC cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg for 26 weeks. |
| Main evidence limit | Key limitation: trial protocols are controlled research settings and should not be translated into open-ended use without label approval. |
Source-linked findings
- Cagrilintide is a long-acting amylin analog studied for appetite and weight-management endpoints, including combination approaches with GLP-1 therapy.
- The standalone compound remains investigational; combination tolerability and GI adverse effects need to be judged from trial protocols, not extrapolated dosing.
- FDA states cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
Protocol and study notes
- Human-trial anchor: Phase 2 dose-finding trial: once-weekly SC cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg for 26 weeks.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 0.25mg once weekly; Alternative: Micro-Stacking: Weeks 1-8, 0.125mg to 0.25mg once weekly.
- Key limitation: trial protocols are controlled research settings and should not be translated into open-ended use without label approval.
- Monitor GI tolerance, hydration, glucose-lowering co-therapy, gallbladder/pancreatitis symptoms, pregnancy status, and weight-regain planning after discontinuation.
Selected medical sources
Independent evidence
Clinical trial regimen(s): Phase 2 dose-finding trial: once-weekly SC cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg for 26 weeks.
Independent safety notes: FDA states cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
Regulatory status: investigational not FDA approved
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Severe gastroparesis or clinically significant delayed gastric emptying: amylin receptor activation further slows gastric motility; may produce complete gastric stasis.
- Concurrent use with CagriSema (cagrilintide + semaglutide fixed combination): results in double-dosing of cagrilintide.
- High-dose stacking with GLP-1 agonists at full therapeutic doses: combined gastric emptying inhibition can produce extreme gastroparesis and severe caloric restriction; always micro-dose when stacking.
- Type 1 diabetes mellitus without insulin dose adjustment: amylin agonism slows glucose absorption; risk of unpredictable hypoglycemia.
- Hypoglycemia unawareness: gastroparesis caused by amylin agonism delays glucose absorption and may blunt early hypoglycemia recognition.
- Pregnancy: insufficient safety data.
- Breastfeeding: insufficient safety data.
- Known hypersensitivity or anaphylaxis to cagrilintide or any formulation excipient.
- Active bowel obstruction or severe inflammatory bowel disease: GI motility impairment will worsen symptoms.
- Planned general anesthesia or elective surgery: additive gastric emptying delay with any co-administered GLP-1 agent significantly raises pulmonary aspiration risk; follow pre-operative fasting and drug discontinuation protocols.
- End-stage renal disease: safety data limited.
- Pediatric use: safety and efficacy not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Nausea: most common adverse effect; driven by amylin receptor activation in the area postrema (the brain's "nausea center"); typically mild to moderate in monotherapy.
- Nausea significantly amplified when stacked with GLP-1 agonists: dual-pathway stimulation of GI motility centers produces additive nausea far exceeding either compound alone.
- Vomiting: more common in stacking protocols than monotherapy.
- Extreme fullness and early satiety: primary pharmacological effect; can become pathological at high combined doses with GLP-1 agonists.
- Inadequate caloric intake: at high stack doses, subjects may be physically unable to consume sufficient calories; requires active monitoring.
- Gastroparesis: clinically significant delayed gastric emptying; risk amplified substantially when combined with any GLP-1 compound.
- Diarrhea.
- Constipation.
- Abdominal pain and cramping.
- Decreased appetite: intended pharmacological effect.
- Hypoglycemia: low risk in monotherapy; elevated risk when stacked with insulin, sulfonylureas, or high-dose GLP-1 agonists; delayed gastric absorption alters glucose uptake kinetics.
- Fatigue and lethargy: frequently secondary to insufficient caloric intake, particularly during aggressive stacking protocols.
- Headache.
- Dizziness.
- Injection site reactions: redness, swelling, itching; well-tolerated in most subjects.
- Administration site conditions: higher rate of injection site adverse events versus semaglutide monotherapy in combination trial data (RR 3.27 in CagriSema vs. semaglutide alone).
- Elevated LDL-C: modestly higher LDL cholesterol observed in combination therapy versus semaglutide alone (MD +0.29 mmol/L); clinical significance uncertain.
- Higher serious adverse event rate in monotherapy versus semaglutide: observed in meta-analysis data (RR 1.83); warrants careful monitoring.
- Pulmonary aspiration risk under general anesthesia: significantly elevated in combination with any GLP-1 agent.
- Rapid weight regain upon discontinuation: expected without lifestyle intervention.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: